BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ishii-watabe A, Shibata H, Nishimura K, Hosogi J, Aoyama M, Nishimiya K, Saito Y. Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan. Bioanalysis 2018;10:95-105. [DOI: 10.4155/bio-2017-0186] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Hasan MM, Laws M, Jin P, Rahman KM. Factors influencing the choice of monoclonal antibodies for antibody-drug conjugates. Drug Discov Today 2021:S1359-6446(21)00409-8. [PMID: 34597756 DOI: 10.1016/j.drudis.2021.09.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Tanaka Y, Takahashi T, Sumi M, Hagino O, Van Hoogstraten H, Xu C, Kato N, Kameda H. Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials. Mod Rheumatol 2021:roab066. [PMID: 34915576 DOI: 10.1093/mr/roab066] [Reference Citation Analysis]
3 López-Laguna H, Voltà-Durán E, Parladé E, Villaverde A, Vázquez E, Unzueta U. Insights on the emerging biotechnology of histidine-rich peptides. Biotechnol Adv 2021;:107817. [PMID: 34418503 DOI: 10.1016/j.biotechadv.2021.107817] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
4 Yokoyama Y, Sawada K, Aoyama N, Yoshimura N, Sako M, Hirai F, Kashiwagi N, Suzuki Y. Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients With Inflammatory Bowel Disease Showing Lost Response to Infliximab. J Crohns Colitis. 2020;14:1264-1273. [PMID: 32166331 DOI: 10.1093/ecco-jcc/jjaa051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
5 Johnson D, Simmons E, Abdeen S, Kinne A, Parmer E, Rinker S, Thystrup J, Ramaswamy S, Bowsher RR. Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain. Sci Rep 2021;11:15467. [PMID: 34326436 DOI: 10.1038/s41598-021-95055-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Laurén A, Goodman J, Blaes J, Cook J, Cowan KJ, Dahlbäck M, Grudzinska-Goebel J, McManus D, Nelson R, Pihl S, Timmerman P. A strategic approach to nonclinical immunogenicity assessment: a recommendation from the European Bioanalysis Forum. Bioanalysis 2021;13:537-49. [PMID: 33729007 DOI: 10.4155/bio-2021-0028] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Jiang Z, Kamerud J, Zhang M, Ruiz CC, Guadiz C, Fichtner A, Gorovits B. Strategies to develop highly drug-tolerant cell-based neutralizing antibody assay: neutralizing antidrug antibodies extraction and drug depletion. Bioanalysis 2020;12:1279-93. [PMID: 32945693 DOI: 10.4155/bio-2020-0091] [Reference Citation Analysis]
8 Chirmule N, Khare R, Khandekar A, Jawa V. Failure Mode and Effects Analysis (FMEA) for Immunogenicity of Therapeutic Proteins. J Pharm Sci 2020;109:3214-22. [PMID: 32721473 DOI: 10.1016/j.xphs.2020.07.019] [Reference Citation Analysis]
9 Jordan G, Staack RF. Toward comparability of anti-drug antibody assays: is the amount of anti-drug antibody–reagent complexes at cut-point (CP-ARC) the missing piece? Bioanalysis 2020;12:1021-31. [DOI: 10.4155/bio-2020-0143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
10 Bano N, McKelvey T, Spear N, Yang TY, Shankar G, Schantz A. Analysis of regulatory guidance on antidrug antibody testing for therapeutic protein products. Bioanalysis 2019;11:2283-96. [PMID: 31845602 DOI: 10.4155/bio-2019-0241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Todoroki K, Mizuno H, Sugiyama E, Toyo’oka T. Bioanalytical methods for therapeutic monoclonal antibodies and antibody–drug conjugates: A review of recent advances and future perspectives. Journal of Pharmaceutical and Biomedical Analysis 2020;179:112991. [DOI: 10.1016/j.jpba.2019.112991] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
12 Suzuki T, Tada M, Ishii-watabe A. Development of anti-drug monoclonal antibody panels against adalimumab and infliximab. Biologicals 2020;63:39-47. [DOI: 10.1016/j.biologicals.2019.12.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
13 Pihl S, van der Strate BW, Golob M, Ryding J, Vermet L, Jaitner B, Goodman J, Timmerman P. EBF recommendation on practical management of critical reagents for antidrug antibody ligand-binding assays. Bioanalysis 2019;11:1787-98. [PMID: 31657235 DOI: 10.4155/bio-2019-0248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
14 Nishimura K, Shibata H, Aoyama M, Hosogi J, Kadotsuji K, Minoura K, Mori T, Nakamura T, Nishimiya K, Nomura T, Saito T, Soma M, Wakabayashi H, Sakamoto N, Niimi S, Katori N, Saito Y, Ishii-watabe A. Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study. Bioanalysis 2019;11:509-24. [DOI: 10.4155/bio-2018-0178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Ishii-watabe A, Kuwabara T. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies. Drug Metabolism and Pharmacokinetics 2019;34:64-70. [DOI: 10.1016/j.dmpk.2018.11.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
16 Kubiak RJ, Zhang J, Ren P, Yang H, Roskos LK. Excessive outlier removal may result in cut points that are not suitable for immunogenicity assessments. Journal of Immunological Methods 2018;463:105-11. [DOI: 10.1016/j.jim.2018.10.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
17 Neubert H, Olah T, Lee A, Fraser S, Dodge R, Laterza O, Szapacs M, Alley SC, Saad OM, Amur S, Chen L, Cherry E, Cho SJ, Cludts I, Donato LD, Edmison A, Ferrari L, Garofolo F, Haidar S, Hopper S, Hottenstein S, Ishii-Watabe A, Kassim S, Kurki P, Lima Santos GM, Miscoria G, Palandra J, Pedras-Vasconcelos J, Piccoli S, Rogstad S, Saito Y, Savoie N, Sikorski T, Spitz S, Staelens L, Verthelyi D, Vinter S, Wadhwa M, Wang YM, Welink J, Weng N, Whale E, Woolf E, Wu J, Yan H, Yu H, Zhou S. 2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 - PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies' inputs on bioanalysis, biomarkers and immunogenicity). Bioanalysis 2018;10:1897-917. [PMID: 30488729 DOI: 10.4155/bio-2018-0285] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
18 Schreitmüller T, Barton B, Zharkov A, Bakalos G. Comparative immunogenicity assessment of biosimilars. Future Oncol 2019;15:319-29. [PMID: 30278780 DOI: 10.2217/fon-2018-0553] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
19 Komaba J, Hosogi J, Igarashi H, Kamimori H, Nakai K, Nakamura T, Kawai Y, Sano Y, Yamaguchi T. The ninth Japan Bioanalysis Forum symposium. Bioanalysis 2018;10:1467-71. [PMID: 30198754 DOI: 10.4155/bio-2018-0198] [Reference Citation Analysis]
20 Egging D, Verhagen J, Laat-arts KD, Wit BD, Boekel TV, Buurman M, Eigenhuijsen J, Lubbers-geuijen K, Mulder R. Sensitivity and drug tolerance of antidrug antibody assays in relation to positive control characteristics. Bioanalysis 2018;10:1289-306. [DOI: 10.4155/bio-2018-0091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 Iwamoto N, Yokoyama K, Takanashi M, Yonezawa A, Matsubara K, Shimada T. Application of nSMOL coupled with LC-MS bioanalysis for monitoring the Fc-fusion biopharmaceuticals Etanercept and Abatacept in human serum. Pharmacol Res Perspect 2018;6:e00422. [PMID: 30062014 DOI: 10.1002/prp2.422] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]